Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46


Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study.

Samiei M, Vahidi M, Rezaee O, Yaraghchi A, Daneshmand R.

Iran J Psychiatry Behav Sci. 2016 Sep 4;10(3):e7988. eCollection 2016 Sep.


mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, Galli A.

J Neurosci. 2015 Jun 10;35(23):8843-54. doi: 10.1523/JNEUROSCI.0887-15.2015.


The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial.

Mirabzadeh A, Kimiaghalam P, Fadai F, Samiei M, Daneshmand R.

Basic Clin Neurosci. 2014 Summer;5(3):212-7.


Placebo response in antipsychotic clinical trials: a meta-analysis.

Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA.

JAMA Psychiatry. 2014 Dec 1;71(12):1409-21. doi: 10.1001/jamapsychiatry.2014.1319. Erratum in: JAMA Psychiatry. 2015 Jan;72(1):96.


Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder.

Keedy SK, Bishop JR, Weiden PJ, Sweeney JA, Rosen C, Marvin R, Reilly JL.

Schizophr Res. 2014 Oct;159(1):101-6. doi: 10.1016/j.schres.2014.07.028. Epub 2014 Aug 8.


Dose equivalents for second-generation antipsychotics: the minimum effective dose method.

Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM.

Schizophr Bull. 2014 Mar;40(2):314-26. doi: 10.1093/schbul/sbu001. Epub 2014 Feb 3.


An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.

Pandina G, Kushner S, Karcher K, Haas M.

Child Adolesc Psychiatry Ment Health. 2012 Jun 7;6(1):23. doi: 10.1186/1753-2000-6-23.


Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Turner EH, Knoepflmacher D, Shapley L.

PLoS Med. 2012;9(3):e1001189. doi: 10.1371/journal.pmed.1001189. Epub 2012 Mar 20.


Treatment mechanisms: traditional and new antipsychotic drugs.

Tamminga CA.

Dialogues Clin Neurosci. 2000 Sep;2(3):281-6.


Antipsychotic medication for early episode schizophrenia.

Bola J, Kao D, Soydan H.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006374. doi: 10.1002/14651858.CD006374.pub2. Review.


Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia.

Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, Xie S, Zhang X, Li T, Ma C, Yu W, Parsons B, Schou M.

Neuropsychiatr Dis Treat. 2011;7:77-85. doi: 10.2147/NDT.S16664. Epub 2011 Mar 4.


Risperidone in Indian patients with schizophrenia.

Agarwal AK, Bashyam VS, Channabasavanna SM, Dhavale HS, Khan MA, Khanna S, Pradhan PV, Katiyar M, Rajkumar R, Niazi FR, Jalali RK, Gowrishankar R, Mishra SK, Sood OP.

Indian J Psychiatry. 1998 Jul;40(3):247-53.


Management of schizophrenia : an update.

Kulhara P.

Indian J Psychiatry. 1998 Apr;40(2):120-34.


Reemergence of positive symptoms of schizophrenia during the course of treatment with risperidone.

Bajaj P, Nihalani N, Shah N, Desai N, Shinde V, Raut N.

Indian J Psychiatry. 1999 Apr;41(2):96-9.


Risperidone in schizophrenia.

Agashe M, Dhawale DM, Cozma G, Mogre V.

Indian J Psychiatry. 1999 Jan;41(1):54-9.


Once daily risperidone in treatment of schizophrenia.

Agarwal V, Chadda RK.

Indian J Psychiatry. 2001 Jan;43(1):32-5.


Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.

BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21.


Paliperidone: the evidence of its therapeutic value in schizophrenia.

Kantrowitz J, Citrome L.

Core Evid. 2008 Jul 31;2(4):261-71.

Supplemental Content

Support Center